by George Ciuciureanu | Apr 30, 2025 | Events, Health
Augurex to participate in the SPARTAN 2025 Annual Meeting, taking place May 9–10 in Toronto, Canada. Featuring SPINEstat™, a Health Canada-approved, first-in-class blood test for the early diagnosis and monitoring of axial spondyloarthritis (axSpA). Vancouver, Canada...
by George Ciuciureanu | Apr 25, 2025 | Events, Health
Augurex to attend British Society for Rheumatology 2025 Annual Meeting in Manchester, UK Highlighting biomarker-based diagnostic innovations for RA and axSpA Vancouver, Canada – April 25, 2025 – Augurex Life Sciences Corp., a leader in biomarker-based diagnostics for...
by George Ciuciureanu | Apr 24, 2025 | Events, Health
Augurex to attend CCR East 2025 and present new research on 14-3-3eta auto-antibodies as a diagnostic marker for axial spondyloarthritis (axSpA). Augurex will be exhibiting at booth #66, showcasing how the 14-3-3eta test aids in the diagnosis and monitoring of...
by George Ciuciureanu | Apr 22, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing...
by George Ciuciureanu | Apr 16, 2025 | Health, News
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has been approved by Health Canada. This approval marks an important milestone in addressing a significant global unmet need in axSpA. As an inflammatory autoimmune...
by George Ciuciureanu | Apr 15, 2025 | Events, Health
Vancouver, Canada – April 15, 2025 – Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that multiple scientific abstracts have been accepted for presentation at major international rheumatology and diagnostics conferences...
